RNA test identifies large B-cell lymphoma subtypes
Answers from the Lab
Precise diagnosis is key to choosing the optimal chemotherapy for large B-cell lymphoma. In this test-specific episode of the "Answers From the Lab" podcast, Lisa Rimsza, M.D., explains how Mayo Clinic Laboratories' unique PM3CX test accurately distinguishes among multiple subtypes of this cancer.
"PM3CX is a qualitative RNA test," Dr. Rimsza says. "It first tells you if the patient has primary mediastinal large B-cell lymphoma or diffuse large B-cell lymphoma (DLBCL). The test can also identify subtypes of DLBCL."
Using gene expression profiling, the test avoids challenges associated with immunostaining and biopsies of delicate tissue. "The molecular test is very accurate and reproducible," Dr. Rimsza says. "There is no other molecular test like this, for this disease."
Test results can directly impact treatment decisions. "Clinicians need to know whether a patient has the more typical DLBCL — which gets one type of chemotherapy — or in fact has the primary mediastinal large B-cell type, which gets a different chemotherapy," Dr. Rimsza says.
Listen to learn more about Mayo Clinic Laboratories' PM3CX test.
Note: Podcasts will not play back on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.
Only indicated for formalin-fixed paraffin-embedded specimens from patients diagnosed with large B-cell lymphoma.
Submit only 1 of the following specimens:
Lisa Rimsza, M.D., explains how Mayo Clinic Laboratories' unique PM3CX test can accurately determine subtypes of large B-cell lymphoma. Precise diagnosis is critical to choosing appropriate chemotherapy.
Patients with elevated LDL or "bad" cholesterol face even greater risk if their levels of small dense LDL cholesterol are also high. Vlad Vasile, M.D., Ph.D., and Leslie Donato, Ph.D., explain how Mayo Clinic Laboratories' sdLDL-c assay measures concentrations of the small dense LDL subtype, to better guide clinical care.
Identifying a precise genetic cause of hearing loss impacts clinical management. Nicole Boczek, Ph.D., and Melanie Meyer, M.S., CGC, explain how Mayo Clinic Laboratories' updated panel yields comprehensive results for optimal patient care.